Please login to the form below

Not currently logged in
Email:
Password:

Gilead

This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.

Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis

Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis

In August 2020, the US Food and Drug Administration (FDA) rejected Gilead’s Jyseleca, handing the company a complete response letter (CRL). ... The FDA has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose,”

Latest news

More from news
Approximately 183 fully matching, plus 389 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and

  • The search for effective drug treatments for COVID-19 The search for effective drug treatments for COVID-19

    The European Commission has signed a joint procurement agreement for Gilead’s COVID-19 antiviral treatment remdesivir. ... Since January, Gilead has taken multiple steps to ramp up production and rapidly build supply in recognition of the lengthy

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.

  • Working together against COVID-19 Working together against COVID-19

    There were questions asked directly to Gilead, and also peers, about Compassionate Use and Extended Access. ... Subsequently, Gilead dropped remdesivir’s orphan drug designation based on its potential as a coronavirus treatment.

  • COVID-19: the race to find a vaccine COVID-19: the race to find a vaccine

    The antiviral subcategory is a key focal point, with drugs such as Gilead Sciences’ remdesivir being tested in tens of trials and attracting the attention of the general public and world

More from intelligence
Approximately 5 fully matching, plus 52 partially matching documents found.

Latest appointments

More from appointments
Approximately 6 fully matching, plus 20 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 16 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics